Phase 3 ONWARD3 data demonstrate sustained skin clearance, pruritus relief, and quality of life improvements with ...

Experts at the 2026 Fall Clinical Dermatology Conference review landmark drug approvals, emerging pipelines, and updated ...

Serum ferritin threshold of less than or equal to 20ng/mL is suggested for children ages 9 months to 4 years. HealthDay News — In guidelines issued by the American Society of Hematology and published ...

The effect of semaglutide on major adverse cardiovascular events (MACE) is only partially due to known risk factors, according to a study published online September 23 in the European Heart Journal.

In national prospective study, 2.9% of those undergoing anesthesia reported receiving GLP-1 receptor agonists.

Officials say low vaccination rates in rural communities are fueling the spread of the highly contagious virus.

Phase 3 PROPEL 3 trial results show daily oral infigratinib significantly improved annualized height velocity and height Z-scores compared with placebo in children with achondroplasia.

Tasimelteon significantly advanced sleep onset by 42.5 minutes in adults with delayed sleep-wake phase disorder, according to topline phase 3 data.

Supported by phase 3 FENhance 1, FENhance 2, and FENtrepid trial results, oral fenebrutinib reduced relapse rates and showed numerical benefits in delaying disability progression across the MS ...

The Food and Drug Administration (FDA) has approved Weltruza ™ (olanzapine) as the first once-monthly subcutaneous long-acting injectable (LAI) for the treatment of schizophreni ...

Findings show reductions in inappropriate medication, medication underuse and overuse, and missing vaccinations ...

Key takeaways from the 26th annual Fall Clinical Dermatology Conference held in Las Vegas, Nevada were published.